BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity.
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., Adolf, G.R.(2009) Clin Cancer Res 15: 3094-3102
- PubMed: 19383823 
- DOI: https://doi.org/10.1158/1078-0432.CCR-08-2445
- Primary Citation of Related Structures:  
3FC2 - PubMed Abstract: 
Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers. To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.
Organizational Affiliation: 
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.